In vitro evaluation of a double-stranded self-complementary adeno-associated virus type2 vector in bone marrow stromal cells for bone healing

Genetic Vaccines and Therapy

Volumn 9, Issue , 2011, Pages

  Alaee, Farhang ^a   Sugiyama, Osamu ^a   Virk, Mandeep S ^a   Tang, Ying ^b   Wang, Bing ^b   Lieberman, Jay R ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BONE MORPHOGENETIC PROTEIN 2; ENHANCED GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; SELF COMPLEMENTARY ADENOASSOCIATED VIRAL VECTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CELL TYPE; CONTROLLED STUDY; EX VIVO GENE TRANSFER; FRACTURE HEALING; GENE OVEREXPRESSION; GENETIC CODE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; RAT; STROMA CELL; TRANSGENE; VIRUS GENOME;

ADENO-ASSOCIATED VIRUS; RATTUS;

EID: 79951952127     PISSN: None     EISSN: 14790556     Source Type: Journal    
DOI: 10.1186/1479-0556-9-4     Document Type: Article

References (55)

1. Colterjohn NR, Bednar DA. Procurement of bone graft from the iliac crest. An operative approach with decreased morbidity. J Bone Joint Surg Am 1997, 79:756-759.
2. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R, Aro H, Atar D, Bishay M, Borner MG, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002, 84-A:2123-2134.
3. Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, LaForte AJ, Yin S. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001, 83-A(Suppl 1):S151-158. 1425155, 11314793.
4. Marsell R, Einhorn TA. Emerging bone healing therapies. J Orthop Trauma 24(Suppl 1):S4-8.
5. Chen NF, Smith ZA, Stiner E, Armin S, Sheikh H, Khoo LT. Symptomatic ectopic bone formation after off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion. J Neurosurg Spine 12:40-46. 10.3171/2009.4.SPINE0876, 20043763.
6. Shields LB, Raque GH, Glassman SD, Campbell M, Vitaz T, Harpring J, Shields CB. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine (Phila Pa 1976) 2006, 31:542-547.
7. Baltzer AW, Lattermann C, Whalen JD, Wooley P, Weiss K, Grimm M, Ghivizzani SC, Robbins PD, Evans CH. Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Ther 2000, 7:734-739. 10.1038/sj.gt.3301166, 10822299.
8. Evans CH, Liu FJ, Glatt V, Hoyland JA, Kirker-Head C, Walsh A, Betz O, Wells JW, Betz V, Porter RM, et al. Use of genetically modified muscle and fat grafts to repair defects in bone and cartilage. Eur Cell Mater 2009, 18:96-111.
9. Giannoudis PV, Tzioupis CC, Tsiridis E. Gene therapy in orthopaedics. Injury 2006, 37(Suppl 1):S30-40. 10.1016/j.injury.2006.02.038, 16581075.
10. Hannallah D, Peterson B, Lieberman JR, Fu FH, Huard J. Gene therapy in orthopaedic surgery. Instr Course Lect 2003, 52:753-768.
11. Hsu WK, Sugiyama O, Park SH, Conduah A, Feeley BT, Liu NQ, Krenek L, Virk MS, An DS, Chen IS, Lieberman JR. Lentiviral-mediated BMP-2 gene transfer enhances healing of segmental femoral defects in rats. Bone 2007, 40:931-938. 10.1016/j.bone.2006.10.030, 17236835.
12. Lieberman JR, Daluiski A, Stevenson S, Wu L, McAllister P, Lee YP, Kabo JM, Finerman GA, Berk AJ, Witte ON. The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am 1999, 81:905-917.
13. Virk MS, Conduah A, Park SH, Liu N, Sugiyama O, Cuomo A, Kang C, Lieberman JR. Influence of short-term adenoviral vector and prolonged lentiviral vector mediated bone morphogenetic protein-2 expression on the quality of bone repair in a rat femoral defect model. Bone 2008, 42:921-931. 10.1016/j.bone.2007.12.216, 18295562.
14. Sinn PL, Sauter SL, McCray PB. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production. Gene Ther 2005, 12:1089-1098. 10.1038/sj.gt.3302570, 16003340.
15. Wilson CA, Cichutek K. The US and EU regulatory perspectives on the clinical use of hematopoietic stem/progenitor cells genetically modified ex vivo by retroviral vectors. Methods Mol Biol 2009, 506:477-488. full_text, 19110646.
16. Ehrhardt A, Haase R, Schepers A, Deutsch MJ, Lipps HJ, Baiker A. Episomal vectors for gene therapy. Curr Gene Ther 2008, 8:147-161. 10.2174/156652308784746440, 18537590.
17. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996, 3:137-144.
18. Yang Y, Su Q, Wilson JM. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol 1996, 70:7209-7212. 190774, 8794368.
19. Berns KI, Giraud C. Biology of adeno-associated virus. Curr Top Microbiol Immunol 1996, 218:1-23.
20. Tang Y, Cummins J, Huard J, Wang B. AAV-directed muscular dystrophy gene therapy. Expert Opin Biol Ther 10:395-408. 10.1517/14712591003604690, 20132060.
21. Lai CM, Lai YK, Rakoczy PE. Adenovirus and adeno-associated virus vectors. DNA Cell Biol 2002, 21:895-913. 10.1089/104454902762053855, 12573049.
22. McCarty DM, Young SM, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 2004, 38:819-845. 10.1146/annurev.genet.37.110801.143717, 15568995.
23. Conrad CK, Allen SS, Afione SA, Reynolds TC, Beck SE, Fee-Maki M, Barrazza-Ortiz X, Adams R, Askin FB, Carter BJ, et al. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther 1996, 3:658-668.
24. Dudus L, Anand V, Acland GM, Chen SJ, Wilson JM, Fisher KJ, Maguire AM, Bennett J. Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV. Vision Res 1999, 39:2545-2553. 10.1016/S0042-6989(98)00308-3, 10396623.
25. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996, 70:8098-8108. 190884, 8892935.
26. Mueller C, Flotte TR. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 2008, 15:858-863. 10.1038/gt.2008.68, 18418415.
27. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998, 72:2224-2232. 109519, 9499080.
28. Wang B, Li J, Fu FH, Chen C, Zhu X, Zhou L, Jiang X, Xiao X. Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther 2008, 15:1489-1499. 10.1038/gt.2008.104, 18563184.
29. Sugiyama O, An DS, Kung SP, Feeley BT, Gamradt S, Liu NQ, Chen IS, Lieberman JR. Lentivirus-mediated gene transfer induces long-term transgene expression of BMP-2 in vitro and new bone formation in vivo. Mol Ther 2005, 11:390-398. 10.1016/j.ymthe.2004.10.019, 15727935.
30. Lieberman JR, Le LQ, Wu L, Finerman GA, Berk A, Witte ON, Stevenson S. Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res 1998, 16:330-339. 10.1002/jor.1100160309, 9671928.
31. Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I, Tagliafico E, Ferrari S, Robey PG, Riminucci M, Bianco P. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007, 131:324-336. 10.1016/j.cell.2007.08.025, 17956733.
32. Pagnotto MR, Wang Z, Karpie JC, Ferretti M, Xiao X, Chu CR. Adeno-associated viral gene transfer of transforming growth factor-beta1 to human mesenchymal stem cells improves cartilage repair. Gene Ther 2007, 14:804-813. 10.1038/sj.gt.3302938, 17344902.
33. Rehman KK, Trucco M, Wang Z, Xiao X, Robbins PD. AAV8-mediated gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of diabetes in NOD mice. Mol Ther 2008, 16:1409-1416. 10.1038/mt.2008.116, 18560422.
34. Sagazio A, Xiao X, Wang Z, Martari M, Salvatori R. A single injection of double-stranded adeno-associated viral vector expressing GH normalizes growth in GH-deficient mice. J Endocrinol 2008, 196:79-88. 10.1677/JOE-07-0312, 18180319.
35. Goodrich LR, Choi VW, Carbone BA, McIlwraith CW, Samulski RJ. Ex vivo serotype-specific transduction of equine joint tissue by self-complementary adeno-associated viral vectors. Hum Gene Ther 2009, 20:1697-1702. 10.1089/hum.2009.030, 2861962, 19642864.
36. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, Chen C, Li J, Xiao X. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005, 23:321-328. 10.1038/nbt1073, 15735640.
37. Vandendriessche T, Thorrez L, Acosta-Sanchez A, Petrus I, Wang L, Ma L, L DEW, Iwasaki Y, Gillijns V, Wilson JM, et al. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost 2007, 5:16-24. 10.1111/j.1538-7836.2006.02220.x, 17002653.
38. Chng K, Larsen SR, Zhou S, Wright JF, Martiniello-Wilks R, Rasko JE. Specific adeno-associated virus serotypes facilitate efficient gene transfer into human and non-human primate mesenchymal stromal cells. J Gene Med 2007, 9:22-32. 10.1002/jgm.990, 17154338.
39. Rehman KK, Wang Z, Bottino R, Balamurugan AN, Trucco M, Li J, Xiao X, Robbins PD. Efficient gene delivery to human and rodent islets with double-stranded (ds) AAV-based vectors. Gene Ther 2005, 12:1313-1323. 10.1038/sj.gt.3302530, 15858610.
40. Veldwijk MR, Sellner L, Stiefelhagen M, Kleinschmidt JA, Laufs S, Topaly J, Fruehauf S, Zeller WJ, Wenz F. Pseudotyped recombinant adeno-associated viral vectors mediate efficient gene transfer into primary human CD34(+) peripheral blood progenitor cells. Cytotherapy 12:107-112. 10.3109/14653240903348293, 19929455.
41. Lattermann C, Oxner WM, Xiao X, Li J, Gilbertson LG, Robbins PD, Kang JD. The adeno associated viral vector as a strategy for intradiscal gene transfer in immune competent and pre-exposed rabbits. Spine (Phila Pa 1976) 2005, 30:497-504.
42. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996, 70:3227-3234. 190186, 8627803.
43. Hauck B, Zhao W, High K, Xiao W. Intracellular viral processing, not single-stranded DNA accumulation, is crucial for recombinant adeno-associated virus transduction. J Virol 2004, 78:13678-13686. 10.1128/JVI.78.24.13678-13686.2004, 533901, 15564477.
44. Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2003, 10:2105-2111. 10.1038/sj.gt.3302133, 14625564.
45. McMahon JM, Conroy S, Lyons M, Greiser U, O'Shea C, Strappe P, Howard L, Murphy M, Barry F, O'Brien T. Gene transfer into rat mesenchymal stem cells: a comparative study of viral and nonviral vectors. Stem Cells Dev 2006, 15:87-96. 10.1089/scd.2006.15.87, 16522166.
46. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998, 72:1438-1445. 124624, 9445046.
47. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002, 76:791-801. 10.1128/JVI.76.2.791-801.2002, 136844, 11752169.
48. Stender S, Murphy M, O'Brien T, Stengaard C, Ulrich-Vinther M, Soballe K, Barry F. Adeno-associated viral vector transduction of human mesenchymal stem cells. Eur Cell Mater 2007, 13:93-99. discussion 99.
49. Gafni Y, Pelled G, Zilberman Y, Turgeman G, Apparailly F, Yotvat H, Galun E, Gazit Z, Jorgensen C, Gazit D. Gene therapy platform for bone regeneration using an exogenously regulated, AAV-2-based gene expression system. Mol Ther 2004, 9:587-595. 10.1016/j.ymthe.2003.12.009, 15093189.
50. Koefoed M, Ito H, Gromov K, Reynolds DG, Awad HA, Rubery PT, Ulrich-Vinther M, Soballe K, Guldberg RE, Lin AS, et al. Biological effects of rAAV-caAlk2 coating on structural allograft healing. Mol Ther 2005, 12:212-218. 10.1016/j.ymthe.2005.02.026, 16043092.
51. Ito H, Koefoed M, Tiyapatanaputi P, Gromov K, Goater JJ, Carmouche J, Zhang X, Rubery PT, Rabinowitz J, Samulski RJ, et al. Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med 2005, 11:291-297. 10.1038/nm1190, 1364464, 15711561.
52. Yazici C, Takahata M, Reynolds DG, Xie C, Samulski RJ, Samulski J, Beecham EJ, Gertzman AA, Spilker M, Zhang X, et al. Self-complementary AAV2.5-BMP2-coated Femoral Allografts Mediated Superior Bone Healing Versus Live Autografts in Mice With Equivalent Biomechanics to Unfractured Femur. Mol Ther 2011,
53. Kang Y, Liao WM, Yuan ZH, Sheng PY, Zhang LJ, Yuan XW, Lei L. In vitro and in vivo induction of bone formation based on adeno-associated virus-mediated BMP-7 gene therapy using human adipose-derived mesenchymal stem cells. Acta Pharmacol Sin 2007, 28:839-849. 10.1111/j.1745-7254.2007.00583.x, 17506943.
54. Wang J, Woo S, Li J, Xiao X. Adeno-associated virus transduction efficiency in fibroblasts is species dependent. 46th annual meeting of Orthopaedic Research Society, Paper No 1075 2000,
55. Hansen J, Qing K, Kwon HJ, Mah C, Srivastava A. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol 2000, 74:992-996. 10.1128/JVI.74.2.992-996.2000, 111620, 10623762.